Compass Therapeutics (CMPX) Stock Price, News & Analysis

Company Overview

Compass Therapeutics, Inc. is a clinical‐stage biopharmaceutical company focused on discovering and developing precision immunotherapies to treat cancer and immune‐mediated diseases. The company leverages proprietary antibody engineering and molecular design platforms to generate novel therapeutic candidates with the goal of improving efficacy and safety over existing treatments. Compass’s research efforts target pathways involved in tumor immune evasion as well as chronic inflammatory and fibrotic processes, with a particular emphasis on next‐generation antibody modalities and Fc engineering to optimize immune system engagement.

The company’s pipeline includes multiple antibody candidates in preclinical and early clinical development. Its lead programs are designed to modulate key immune checkpoints and costimulatory receptors, while additional assets address tissue fibrosis and other immune dysregulation disorders. Compass works in collaboration with academic institutions and industry partners to advance its drug candidates through Phase 1 and Phase 2 studies, aiming to deliver first‐in‐class or best‐in‐class therapies for patient populations with high unmet medical needs.

Founded in 2018 as a spin‐out from leading immunology research groups, Compass Therapeutics is headquartered in Cambridge, Massachusetts, in the heart of the Boston biotech cluster. Since its inception, the company has grown its scientific team to include experts in antibody discovery, immuno‐engineering, process development, and clinical operations. Its state‐of‐the‐art laboratory facilities support advanced screening, lead optimization, and translational immunology research.

Compass serves a global patient community by conducting multi‐regional clinical trials across North America, Europe and Asia, and by engaging key opinion leaders in oncology and immunology. The company’s leadership team is composed of seasoned industry veterans with backgrounds at major biopharmaceutical firms and research institutions. This experienced management group oversees strategic alliances, regulatory interactions, and the execution of a development roadmap aimed at bringing innovative immunotherapies to market.

Key Stats

• Today's Range: $2.64 to $2.84
• 50-Day Range: $1.69 to $2.85
• 52-Week Range: $0.87 to $4.08
• Volume: 1.01 million shs
• Average Volume: 978,129 shs
• Market Capitalization: $373.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.67
• Consensus Rating: Buy

Compass Therapeutics Stock Analysis - MarketRank™

Compass Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 602nd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Compass Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 9 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Compass Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Compass Therapeutics are expected to decrease in the coming year, from ($0.36) to ($0.44) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Compass Therapeutics is -6.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Compass Therapeutics is -6.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Compass Therapeutics has a P/B Ratio of 2.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.40% of the float of Compass Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Compass Therapeutics has a short interest ratio ("days to cover") of 7.7.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Compass Therapeutics does not currently pay a dividend.

Dividend Growth

Compass Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.40% of the float of Compass Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Compass Therapeutics has a short interest ratio ("days to cover") of 7.7.

Change versus previous month

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 1.77

News Sentiment

Compass Therapeutics has a news sentiment score of 1.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.00 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Compass Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 3 people have searched for CMPX on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

MarketBeat Follows

3 people have added Compass Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 5.0 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Compass Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $21,100.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

29.80% of the stock of Compass Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

68.43% of the stock of Compass Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CMPX Stock Analysis - Frequently Asked Questions

How have CMPX shares performed this year?

Compass Therapeutics' stock was trading at $1.45 at the beginning of the year. Since then, CMPX stock has increased by 86.2% and is now trading at $2.70.

How were Compass Therapeutics' earnings last quarter?

Compass Therapeutics, Inc. (NASDAQ:CMPX) issued its earnings results on Thursday, May, 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12).

When did Compass Therapeutics IPO?

Compass Therapeutics (CMPX) raised $50 million in an initial public offering (IPO) on the week of November 16th 2020. The company issued 9,000,000 shares at $5.00-$6.00 per share. Citigroup, Credit Suisse and Stifel served as the underwriters for the IPO and Raymond James was co-manager.

How do I buy shares of Compass Therapeutics?

Shares of CMPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Compass Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Compass Therapeutics investors own include Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Walmart (WMT) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CMPX
• CIK: 1738021
• Web: www.compasstherapeutics.com
• Phone: 617-500-8099
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Compass Therapeutics: $12.67
• High Price Target: $32.00
• Low Price Target: $5.00
• Potential Upside/Downside: +369.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.10
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.41)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$49.38 million
• Net Margins: N/A
• Pretax Margin: -6,496.59%
• Return on Equity: -42.47%
• Return on Assets: -38.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.33
• Quick Ratio: 8.33

Sales & Book Value

• Annual Sales: $850 thousand
• Price / Sales: 439.24
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.91 per share
• Price / Book: 2.97

Miscellaneous

• Outstanding Shares: 138,280,000
• Free Float: 97,075,000
• Market Cap: $373.36 million
• Optionable: Not Optionable
• Beta: 1.48